Suppr超能文献

造血干细胞长期存活及移植治疗免疫缺陷:欧洲1968 - 1999年经验报告

Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99.

作者信息

Antoine Corinne, Müller Susanna, Cant Andrew, Cavazzana-Calvo Marina, Veys Paul, Vossen Jaak, Fasth Anders, Heilmann Carsten, Wulffraat Nicolas, Seger Reinhard, Blanche Stéphane, Friedrich Wilhelm, Abinun Mario, Davies Graham, Bredius Robert, Schulz Ansgar, Landais Paul, Fischer Alain

机构信息

Service de Biostatistique et Service d'Immunologie et d'Hématologie Pédiatrique, Hôpital Necker Enfants Malades, Paris, France.

出版信息

Lancet. 2003 Feb 15;361(9357):553-60. doi: 10.1016/s0140-6736(03)12513-5.

Abstract

BACKGROUND

Transplantation of allogeneic haemopoietic stem cells can cure several primary immunodeficiencies. This European report focuses on the long-term results of such procedures done between 1968 and December, 1999, for primary immunodeficiencies.

METHODS

The report includes data from 37 centres in 18 countries, which participated in a European registry for stem-cell transplantation in severe combined immuno deficiencies (SCID) and in other immunodeficiency disorders (non-SCID). 1082 transplants in 919 patients were studied (566 in 475 SCID patients, 512 in 444 non-SCID patients; four procedures excluded owing to insufficient data). Minimum follow-up of 6 months was required.

FINDINGS

In SCID, 3-year survival with sustained engraftment was significantly better after HLA-identical than after mismatched transplantation (77% vs 54%; p=0.002) and survival improved over time. In HLA-mismatched stem-cell transplantation, B(-) SCID had poorer prognosis than B(+) SCID. However, improvement with time occurred in both SCID phenotypes. In non-SCID, 3-year survival after genotypically HLA-matched, phenotypically HLA-matched, HLA-mismatched related, and unrelated-donor transplantation was 71%, 42%, 42%, and 59%, respectively (p=0.0006). Acute graft versus host disease predicted poor prognosis whatever the donor origin except in related HLA-identical transplantation in SCID.

INTERPRETATION

The improvement in survival over time indicates more effective prevention and treatment of disease-related and procedure-related complications--eg, infections and graft versus host disease. An important factor is better prevention of graft versus host disease in the HLA-non-identical setting by use of more efficient methods of T-cell depletion. For non-SCID, stem-cell transplantation can provide a cure, and grafts from unrelated donors are almost as beneficial as those from genetically HLA-identical relatives.

摘要

背景

同种异体造血干细胞移植可治愈多种原发性免疫缺陷病。本欧洲报告聚焦于1968年至1999年12月期间针对原发性免疫缺陷病进行的此类手术的长期结果。

方法

该报告纳入了18个国家37个中心的数据,这些中心参与了欧洲严重联合免疫缺陷(SCID)及其他免疫缺陷疾病(非SCID)干细胞移植登记处。对919例患者的1082例移植进行了研究(475例SCID患者中的566例,444例非SCID患者中的512例;4例手术因数据不足被排除)。要求最短随访6个月。

结果

在SCID中,HLA配型相同的移植后3年持续植入生存率显著高于配型不合移植(77%对54%;p = 0.002),且生存率随时间推移有所改善。在HLA配型不合的干细胞移植中,B(-) SCID的预后比B(+) SCID差。然而,两种SCID表型均随时间有所改善。在非SCID中,基因型HLA匹配、表型HLA匹配、HLA配型不合的亲属及非亲属供体移植后的3年生存率分别为71%、42%、42%和59%(p = 0.0006)。急性移植物抗宿主病预示预后不良,无论供体来源如何,但SCID中HLA配型相同的亲属移植除外。

解读

生存率随时间的改善表明对疾病相关及手术相关并发症(如感染和移植物抗宿主病)的预防和治疗更有效。一个重要因素是通过使用更有效的T细胞清除方法,在HLA不匹配的情况下更好地预防移植物抗宿主病。对于非SCID而言,干细胞移植可实现治愈,非亲属供体的移植物几乎与基因HLA相同的亲属供体的移植物一样有益。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验